Affinity Asset Advisors’s Nurix Therapeutics NRIX Stock Holding History

Affinity Asset Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15M	Hold	967,620	–	–	0.77%	36
2025 Q4	$18.4M	Hold	967,620	–	–	1.05%	31
2025 Q3	$8.94M	Hold	967,620	–	–	0.78%	36
2025 Q2	$11M	Buy	967,620 +156,951	+19%	+$1.7M	1.51%	23
2025 Q1	$9.63M	Sell	810,669 -129,414	-14%	-$2.16M	0.92%	27
2024 Q4	$17.7M	Buy	940,083 +79,684	+9%	+$1.83M	2.37%	15
2024 Q3	$19.3M	Sell	860,399 -51,601	-6%	-$1.17M	2.64%	10
2024 Q2	$19M	Buy	912,000 +101,747	+13%	+$1.58M	2.19%	9
2024 Q1	$11.9M	Buy	810,253 +120,141	+17%	+$1.29M	1.47%	20
2023 Q4	$7.12M	Buy	690,112 +440,112	+176%	+$3.02M	1.3%	24
2023 Q3	$1.97M	Buy	250,000 +150,000	+150%	+$1.37M	0.55%	46
2023 Q2	$999K	Sell	100,000 -50,000	-33%	-$510K	0.35%	51
2023 Q1	$1.33M	Buy	150,000 +70,000	+88%	+$729K	0.44%	50
2022 Q4	$878K	Buy	+80,000	New	+$965K	0.34%	52

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Affinity Asset Advisors's NRIX Position: Q1 2026 in Review

Affinity Asset Advisors held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 967,620 shares worth $15M. The position accounts for 0.77% of the portfolio, ranked #36.

Affinity Asset Advisors first reported a position in NRIX in Q4 2022 and has held it in 14 quarters since. The position peaked at $19.3M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Affinity Asset Advisors held 967,620 shares of Nurix Therapeutics worth $15M as of Q1 2026.
Affinity Asset Advisors left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up 0.77% of Affinity Asset Advisors's portfolio in Q1 2026, its #36 holding.
Affinity Asset Advisors first reported a position in Nurix Therapeutics in Q4 2022 and has held it in 14 quarters since.
Affinity Asset Advisors's Nurix Therapeutics position peaked at $19.3M in Q3 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.